Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the appointment of Melanie Farris to the board as an independent non-executive director.
Ms Farris brings extensive senior executive and board-level experience with prior appointments, including at Factor Therapeutics, Invion and Synapse Australia. She most recently held senior positions at Telix Pharmaceuticals.
Prescient chair Dr James Campbell said, “We are pleased to welcome Melanie to the Board of Directors, especially at this exciting time for the Company. Melanie brings considerable experience in strategy, funding, governance and risk operations and oversight. Her depth of knowledge and expertise in these areas will be invaluable to the Board, shareholders and key stakeholders of Prescient. We look forward to Melanie’s contribution as Prescient continues to deliver on its mission to improve outcomes for cancer patients.”
Ms Farris added, “The PTX-100 Phase 1b results demonstrated strong potential to advance to market a treatment for patients with limited options. This is an exciting time for Prescient, and I look forward to contributing with my Board colleagues and the management team in building value for the Company’s stakeholders as the Phase 2 trial progresses.”